title: Expression of group IIa secretory phospholipase A2 increases with prostate tumor grade.
abstract: OBJECTIVE
  Arachidonate release contributes to prostate tumor progression as arachidonate is metabolized into prostaglandins and leukotrienes, potent mediators of immune suppression, cellular proliferation, tumor motility, and invasion. The group IIa sPLA2 (sPLA2-IIa) can facilitate arachidonate release from cellular phospholipids. We therefore sought to determine whether sPLA2-IIa expression might be related to the development or progression of prostatic adenocarcinoma (CaP).
  
  
  METHODS
  sPLA2-IIa expression was examined by Western blot analyses of CaP cells and xenografts and by immunohistochemistry of benign prostatic hyperplasias and primary human CaPs (n = 101) using a sPLA2-IIa-specific polyclonal antibody.
  
  
  RESULTS
  sPLA2-IIa expression was increased dramatically in the androgen-independent CWR-22R and LNAI CaP cells versus the androgen-dependent CWR-22 and LNCaP cells. Immunohistochemical analyses revealed that sPLA2-IIa expression was also significantly increased with CaP development and advancing disease (trend analysis; Pearson correlation coefficient, P = 0.016). High-grade CaPs showed intense, uniform staining for sPLA2-IIa that was significantly different from that in adjacent benign prostatic hyperplasias (Fisher's exact test, P = 0.021) or low-grade CaP (P = 0.013), both of which showed only focal or weak sPLA2-IIa staining. Further, uniform sPLA2-IIa expression was directly related to the increased proliferative index that typifies advancing disease (P = 0.001). Most significantly, enhanced sPLA2-IIa expression was inversely related to 5-year patient survival (P = 0.015).
  
  
  CONCLUSIONS
  These data show that sPLA2-IIa expression increases with progression to androgen-independence and is highest in the most poorly-differentiated, highest-grade primary human CaP samples.
authors.affiliation: Lilly Research Labs, Cancer Research Division, Eli Lilly and Company, Indianapolis, IN 46285, USA.
authors.forename: J R
authors.initials: JR
authors.lastname: Graff
authors.forename: B W
authors.initials: BW
authors.lastname: Konicek
authors.forename: J A
authors.initials: JA
authors.lastname: Deddens
authors.forename: M
authors.initials: M
authors.lastname: Chedid
authors.forename: B M
authors.initials: BM
authors.lastname: Hurst
authors.forename: B
authors.initials: B
authors.lastname: Colligan
authors.forename: B L
authors.initials: BL
authors.lastname: Neubauer
authors.forename: H W
authors.initials: HW
authors.lastname: Carter
authors.forename: J H
authors.initials: JH
authors.lastname: Carter
mesh_terms: D000728:Androgens / Q000494:pharmacology; D016718:Arachidonic Acid / Q000378:metabolism; D002455:Cell Division; D018450:Disease Progression; D006801:Humans; D007150:Immunohistochemistry; D007527:Isoenzymes / Q000378:metabolism; D008297:Male; D010741:Phospholipases A / Q000378:metabolism*; D054467:Phospholipases A2; D011470:Prostatic Hyperplasia / Q000201:enzymology / Q000473:pathology; D011471:Prostatic Neoplasms / Q000201:enzymology* / Q000473:pathology; D014183:Transplantation, Heterologous; D014407:Tumor Cells, Cultured
chemical_list: D000728:Androgens; D007527:Isoenzymes; D016718:Arachidonic Acid; D010741:Phospholipases A; D054467:Phospholipases A2